- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions
European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
- European Commission
- Public health
- Reference documents
- Register
- Orphan products
- Recombinant human factor IX protein modified with three poin
Pharmaceuticals - Community Register
Community register of orphan medicinal products | GRANTED |
Product information |
Recombinant human factor IX protein modified with three point mutations
| EU orphan designation number: | EU/3/17/1884
|
| Active ingredient: | Recombinant human factor IX protein modified with three point mutations |
| Indication: | Treatment of haemophilia B |
| Sponsor: | Voisin Consulting S.A.R.L.
64, Avenue Pierre Grenier, 92100 Boulogne Billancourt, France |
European Commission procedures |
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 22/06/2017 | Orphan designation | EMA/OD/018/17 | (2017)4370 of 20/06/2017 |
CONTACT
EU links
Directorate General Health & Consumers